Blueprint Medicines (BPMC) Tops Q1 EPS by 11c

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.79), $0.11 better than the analyst estimate of ($1.90). Revenue for the quarter came in at $62.73 million versus the consensus estimate of $38.96 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Goldman starts Talen at buy, sees PJM power tightness boosting earnings
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance